Company expects Phase 3 data readout for zorevunersen in Dravet syndrome in Q3 2027
Stoke plans to initiate rolling U.S. NDA submission for zorevunersen in Q1 2027
Initial safety and efficacy data for STK-002 in ADOA anticipated in H1 2027
Result drivers
Lower collaboration revenue - Q2 revenue declined year over year due to reduced collaboration and licensing revenue, notably the absence of a large Biogen IP license recognition
Higher R&D expenses - Research and development expenses increased due to expanded activities and personnel costs supporting zorevunersen advancement
Launch readiness costs - Sales, general and administrative expenses rose, reflecting growth in personnel and launch readiness expenses
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Stoke Therapeutics Inc is $44.00, about 52.5% above its July 31 closing price of $28.86
STOK•
